Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

被引：122

作者：

Psaty, BM

Weiss, NS

Furberg, CD

Koepsell, TD

Siscovick, DS

Rosendaal, FR

Smith, NL

Heckbert, SR

Kaplan, RC

Lin, DY

Fleming, TR

Wagner, EH

机构：

[1] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA

[2] Univ Washington, Dept Med, Seattle, WA 98101 USA

[3] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA

[4] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA

[5] Univ Washington, Dept Biostat, Seattle, WA 98101 USA

[6] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA

[7] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands

[8] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1999年 / 282卷 / 08期

关键词：

D O I：

10.1001/jama.282.8.786

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：786 / 790

页数：5

共 41 条

[1] Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].

Abenhaim, L ;

Moride, Y ;

Brenot, F ;

Rich, S ;

Benichou, J ;

Kurz, X ;

Higenbottam, T ;

Oakley, C ;

Wouters, E ;

Aubier, M ;

Simonneau, G ;

Begaud, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616

[2] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes [J].

Abraira, C ;

Colwell, J ;

Nuttall, F ;

Sawin, CT ;

Henderson, W ;

Comstock, JP ;

Emanuele, NV ;

Levin, SR ;

Pacold, I ;

Lee, HS ;

Silbert, CK ;

Cxypoliski, R ;

Vasquez, M ;

Kernan, D ;

Niewoehner, C ;

Backes, M ;

Bradley, M ;

Crow, R ;

Rubino, F ;

Bushnell, D ;

Pfeifer, M ;

Service, FJ ;

Howard, B ;

Chew, E ;

Hoogwerf, B ;

Seigel, D ;

Clark, CM ;

Olefsky, JM ;

Porte, D ;

Sussman, KE ;

Johnson, N ;

Christine, B ;

Tir, K ;

Sather, M ;

Day, P ;

Morgan, N ;

Deykin, D ;

Gold, J ;

Huang, P .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) :181-188

[3]

[Anonymous], 1991, JAMA, V265, P3255

[4] Does hyperglycemia really cause coronary heart disease? [J].

BarrettConnor, E .

DIABETES CARE, 1997, 20 (10) :1620-1623

[5] LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE [J].

BROWN, BG ;

ZHAO, XQ ;

SACCO, DE ;

ALBERS, JJ .

CIRCULATION, 1993, 87 (06) :1781-1791

[6] What have we learned from the calcium channel blocker controversy? [J].

Califf, RM ;

Kramer, JM .

CIRCULATION, 1998, 97 (16) :1529-1531

[7] Valvular heart disease associated with fenfluramine-phentermine [J].

Connolly, HM ;

Crary, JL ;

McGoon, MD ;

Hensrud, DD ;

Edwards, BS ;

Edwards, WD ;

Schaff, HV .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588

[8] Diet pills Redux [J].

Curfman, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :629-630

[9] Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions [J].

DagogoJack, S ;

Santiago, JV .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (16) :1802-1817

[10] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].

Davis, BR ;

Cutler, JA ;

Gordon, DJ ;

Furberg, CD ;

Wright, JT ;

Cushman, WC ;

Grimm, RH ;

LaRosa, J ;

Whelton, PK ;

Perry, HM ;

Alderman, MH ;

Ford, CE ;

Oparil, S ;

Francis, C ;

Proschan, M ;

Pressel, S ;

Black, HR ;

Hawkins, CM .

AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360

← 1 2 3 4 5 →